MYGN

Myriad Genetics Inc

Add to Watchlist

Advanced Chart

6.320

+0.22(3.607%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.400

Open

6.220

VWAP

6.25

Vol

2.41M

Mkt Cap

588.04M

Low

6.050

Amount

15.07M

EV/EBITDA(TTM)

Total Shares

90.51M

552.57M

EV/OCF(TTM)

P/S(TTM)

0.67

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

0.00

-100%

0.000

-100%

205.04M

-3.87%

-0.007

-110.88%

208.63M

-0.93%

0.013

-57.33%

Estimates Revision

The market is revising Upward the revenue expectations for Myriad Genetics, Inc. (MYGN) for FY2025, with the revenue forecasts being adjusted by 0.08% over the past three months. During the same period, the stock price has changed by 62.47%.

Revenue Estimates for FY2025

Revise Upward

+0.08%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.14%

In Past 3 Month

Stock Price

Go Up

+62.47%

In Past 3 Month

12 Analyst Rating

28.16% Upside

Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.10 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

7 Hold

2 Sell

Hold

28.16% Upside

Current: 6.320

Low

4.00

Averages

8.10

High

18.00

28.16% Upside

Current: 6.320

Low

4.00

Averages

8.10

High

18.00

Scotiabank

Outperform -> Sector Perform

downgrade

$20 -> $6

2025-05-21

Reason

Scotiabank

Price Target

$20 -> $6

2025-05-21

downgrade

Outperform -> Sector Perform

Reason

As previously reported, Scotiabank downgraded Myriad Genetics to Sector Perform from Outperform with a price target of $6, down from $20. While the firm continues to believe there is opportunity for Myriad to execute against its Oncology and Women's Health business ambitions over the next several years, 2025 is likely to be "a transitional year," the analyst tells investors in a research note. The firm would like to see tangible and consistent progress and also waits for a potential strategy reset under the new CEO before turning more positive on shares, the analyst added.

BofA

Underperform

downgrade

$9 -> $4

2025-05-20

Reason

BofA

Price Target

$9 -> $4

2025-05-20

downgrade

Underperform

Reason

BofA lowered the firm's price target on Myriad Genetics to $4 from $9 and keeps an Underperform rating on the shares following what the firm says was "another disappointing quarter," headlined by a $35M reduction to sales guidance. Myriad has continued to experience headwinds and "the company has not managed to turn the page," says the analyst, who updated estimates accounting for continued headwinds and revised guidance.

Scotiabank

Outperform -> Sector Perform

downgrade

2025-05-20

Reason

Scotiabank

Price Target

2025-05-20

downgrade

Outperform -> Sector Perform

Reason

Scotiabank downgraded Myriad Genetics to Sector Perform from Outperform with a $6 price target.

Morgan Stanley

Tejas Savant

Equal Weight

downgrade

$16 -> $7

2025-05-19

Reason

Morgan Stanley

Tejas Savant

Price Target

$16 -> $7

2025-05-19

downgrade

Equal Weight

Reason

Morgan Stanley analyst Tejas Savant lowered the firm's price target on Myriad Genetics to $7 from $16 and keeps an Equal Weight rating on the shares. A "disappointing" Q1 miss was driven by softness in GeneSight and hereditary cancer tests in the unaffected population, says the analyst, who adds that while the pipeline "holds promise," it "remains a show-me story at this time."

Piper Sandler

Overweight -> NULL

downgrade

2025-05-15

Reason

Piper Sandler

Price Target

2025-05-15

downgrade

Overweight -> NULL

Reason

Piper Sandler lowered the firm's price target on Myriad Genetics to $9 from $12.50 following quarterly results. The firm keeps an Overweight rating on the shares.

Goldman Sachs

Matthew Sykes

Strong Buy

Maintains

$18 → $14

2025-04-17

Reason

Goldman Sachs

Matthew Sykes

Price Target

$18 → $14

2025-04-17

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Myriad Genetics Inc (MYGN.O) is 115.99, compared to its 5-year average forward P/E of -32.39. For a more detailed relative valuation and DCF analysis to assess Myriad Genetics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-32.39

Current PE

115.99

Overvalued PE

400.47

Undervalued PE

-465.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

37.64

Current EV/EBITDA

20.63

Overvalued EV/EBITDA

123.29

Undervalued EV/EBITDA

-48.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

2.34

Current PS

0.67

Overvalued PS

3.17

Undervalued PS

1.51

Financials

Annual

Quarterly

FY2025Q2

YoY :

+0.76%

213.10M

Total Revenue

FY2025Q2

YoY :

-49.80%

-12.50M

Operating Profit

FY2025Q2

YoY :

+800.54%

-330.50M

Net Income after Tax

FY2025Q2

YoY :

+770.73%

-3.57

EPS - Diluted

FY2025Q2

YoY :

+225.40%

-20.50M

Free Cash Flow

FY2025Q2

YoY :

+2.42%

71.23

Gross Profit Margin - %

FY2025Q2

YoY :

-65.93%

-6.00

FCF Margin - %

FY2025Q2

YoY :

+793.89%

-155.09

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

2.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0M

Volume

6-9

Months

850.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.7M

Volume

Months

6-9

2.9M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

2.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

MYGN News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

17:08:31

Myriad Genetics backs FY25 adjusted EPS view (2c)-2c, consensus 1c

2025-08-05

17:06:28

Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c)

2025-07-31 (ET)

2025-07-31

08:35:22

Myriad Genetics announces $200M credit facility

News

9.5

08-06Newsfilter

PinnedMyriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

2.0

08-06Benzinga

Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday

4.5

08-06Benzinga

Stock Market Today: US Futures Edge Higher As Investors Await Earnings From McDonald's, Uber And Walt Disney

People Also Watch

PUMP

ProPetro Holding Corp

Syndax Pharmaceuticals Inc

Bain Capital Specialty Finance Inc

Lexinfintech Holdings Ltd

Digi International Inc

31.850

USD

-0.78%

FAQ

What is Myriad Genetics Inc (MYGN) stock price today?

The current price of MYGN is 6.32 USD — it has increased 3.61 % in the last trading day.

MYGN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

MYGN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Myriad Genetics Inc (MYGN) stock price today?

What is Myriad Genetics Inc (MYGN)'s business?

What is the price predicton of MYGN Stock?

What is Myriad Genetics Inc (MYGN)'s revenue for the last quarter?

What is Myriad Genetics Inc (MYGN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Myriad Genetics Inc (MYGN)'s fundamentals?

How many employees does Myriad Genetics Inc (MYGN). have?

What is Myriad Genetics Inc (MYGN) market cap?